Clinical Trial Results:
A pilot open-label, phase II, single-arm study to evaluate
the association of biomarkers of hormonal resistance and
the mTOR pathway with the clinical efficacy of everolimus
plus letrozole in the first line treatment of postmenopausal
women with hormone positive metastatic or locally
advanced breast cancer
Summary
|
|
EudraCT number |
2013-004139-62 |
Trial protocol |
ES |
Global completion date |
01 Jul 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1 |
This version publication date |
01 May 2019
|
First version publication date |
01 May 2019
|
Other versions |
v2 |
Summary report(s) |
Termination Letter_CRAD001JES13 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.